| 抗血管形成靶向药物的研究进展 |
| |
| 作者姓名： | Jia K Li J |
| |
| 作者单位： | 复旦大学肿瘤医院肿瘤内科,上海,200032 |
| |
| 摘 要： | 肿瘤的生长和转移离不开肿瘤新生血管,这使得抗血管形成治疗成为肿瘤治疗的重要途径之一。血管内皮生长因子及其受体是抗肿瘤治疗的重要靶点之一。本文主要介绍了近年来抗血管形成治疗的一些最新药物研究成果——包括针对血管内皮生长因子的单克隆抗体——贝伐;针对血管内皮生长因子受体的酪氨酸激酶抑制剂——舒尼替尼、索拉非尼等;以及血管内皮生长因子受体的单克隆抗体IMC-1C11等。
|
| 关 键 词： | 肿瘤 血管形成 血管内皮生长因子 抗血管形成 靶向药物 生物治疗 |
| 文章编号： | 1000-467X(2008)04-0442-05 |
| 修稿时间： | 2007年3月16日 |
Anti-angiogenesis targeting drugs: a review |
| |
| Jia K,Li J.Anti-angiogenesis targeting drugs: a review[J].Chinese Journal of Cancer,2008,27(4):442-446. |
| |
| Authors: | Jia Ka Li Jin |
| |
| Institution: | Department of Medical Oncology, Cancer Hospital, Fudan University, Shanghai, 200032, PR China. 0256277@fudan.edu.cn |
| |
| Abstract: | The dependence of tumor growth and metastasis on blood vessels makes tumor angiogenesis a rational target for cancer therapy. One of the key mediators of angiogenesis is vascular endothelial growth factor (VEGF), which is an appealing target for anticancer therapy. The development of anti-VEGF/VEGFR agents and the latest clinical data are reviewed, including bevacizumab as a monoclonal antibody to VEGF, sunitinib and sorafenib as VEGFR tyrosine kinase inhibitors, and IMC-1C11 as VEGFR monoclonal antibody. |
| |
| Keywords: | Neoplasm Angiogenesis Vascular endothelial growth factor Anti-angiogenesis Targeting drug Biological therapy |
| 本文献已被 CNKI 维普 万方数据 PubMed 等数据库收录！ |
